ImmunoGen (NASDAQ: IMGN) today announced that the European Commission has granted
marketing approval for Kadcyla (trastuzumab emtansine; ado-trastuzumab
emtansine in the US) in the European Union (EU).

L & L Energy (NASDAQ: LLEN) announced that on Tuesday it received a formal request from NASDAQ for additional information.

SAP AG (NYSE: SAP) and China Telecom (NYSE: CHA) today announced a strategic partnership in cloud computing through which the SAP® Cloud portfolio will be offered to small and large organizations in China by China Datacom Corporation Limited (CDC), a joint venture between SAP and China Communication Services

The Board of Directors of China Lodging Group (NASDAQ: HTHT) today announced the appointment of Mr. Yongjian Sun as the Director of Company's Board and the acceptance of the resignation from Mr. Matthew Zhang as the Director of Company's Board and the Vice-chairman of the Board, effective immediately.

Mr.

Innate Pharma (OTC: IPHYF) announces today the completion of a private placement directed to US-based specialist institutional investors. The gross amount raised is €20.3 million corresponding to 7.6 million new ordinary shares which will be issued.

Elbit Imaging (NASDAQ: EMITF) ("Elbit") announced today that its subsidiary, Plaza Centers N.V. has announced that further to the announcement dated November 14, 2013, that Plaza has filed for reorganization proceedings with the District Court of Amsterdam in the Netherlands (the "Court") and submitted a restructuring plan to the Court.

Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it
has sold its product royalty rights relating to INCIVO®
(telaprevir) to Janssen Pharmaceutica N.V.

Photronics,
(NASDAQ: PLAB) today
announced an agreement with Dai Nippon Printing Co., Ltd. (DNP)
(7912:Tokyo Stock Exchange) to merge Photronics Semiconductor Mask
Corporation (PSMC), a majority owned subsidiary of Photronics, with DNP
Photomask Technology Taiwan Co., Ltd.

Inovio Pharmaceuticals (NYSE: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon® DNA vaccine to prevent and treat this deadly virus.

Gazit-Globe (NYSE: GZT) announced today that its Board of Directors has declared a quarterly cash dividend of NIS 0.43 per share of its common stock (~U.S.$ 0.12), payable on December 30, 2013 to stockholders of record on December 16, 2013.